Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indomethacin for prevention of post-ERCP pancreatitis
RBR-9q5kr7mPhase 3Recruiting
- Sponsor
- Julio Carlos Pereira Lima
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indomethacin in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (3 arms), sponsored by Julio Carlos Pereira Lima. Started Dec 2025; status: recruiting.
02
Drugs
indomethacin
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on RBR-9q5kr7m.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-9q5kr7m.